The Investor Relation function at seeks to communicate with existing and potential investors. Company’s business operations and important financial information as given in this column, it facilitates the investor to take informed decisions on their investment options.
Share Holding Pattern
|Company Secretary & Compliance officer:||Registrar and Share Transfer Agent:|
|Ms. Sonia Bidla
Hyderabad – 500074
Ph. No:040-24037763, 24036379
|Aarthi Consultants Private Limited
Hyderabad – 500 029
Ph : +91-40-27634445
Fax : +91-40-40-27632184
Email : email@example.com
M/s Concord Drugs Limited (CDL) is incorporated as a Limited Company on 24th April 1995 with the Registrar of companies, Andhra Pradesh. The registered office of the Company is situated at Survey No. 249, Brahmanpally Village, Hayatnagar Mandal, R.R. District, Hyderabad-501511
Concord Drugs Limited was established in 1995 to manufacture and market innovative pharmaceutical products. Concord’s three core product areas are generics, branded and specialty pharmaceuticals. The Company ranks among the top generics suppliers in India. Manufacturers of AMCRYLATE [ISO Amyl 2-Cyanoacrylate] a sterile tissue adhesive used in for sutureless surgeries first time in Asia in collaboration with Indian Institute of Chemical Technology [IICT], Hyderabad a premier CSIR Laboratory. The Technology Information, Forecasting and Assessment Council [TIFAC], New Delhi has helped the company to mass produce ‘AMCRYLATE’ and bring it to Indian consumers. TIFAC was also associated in providing Techno-managerial guidance to the Company. The product is patented in India for Concord Drugs Limited. Further the Company has established Unit-II or Phase-II at Roorkee, Uttrakhand in 2005 for manufacturing of Tablets & Capsules.
AMCRYLATE is non-pigmented, non-toxic, non-allergic, bacteriostatic and bio-static adhesive. It allows rapid wound closure with minimal scarring, reduces the risk of post surgical infection and trauma, besides being simple and safe to use.
Also set-up a plant for Small Volume Parenterals in liquid ampoules/vials and powder Parenterals and also Tablets & Capsules with Betalactum & Non-Betalactum both sections. The Company is listed on Ahmedabad, Pune and Madras Stock Exchanges.
MAIN OBJECTS OF THE COMPANY:
The Company is engaged in the business of manufacturing, processing, finishing, preparing for market, stocking, buying, selling, exporting, distributing and generally deal in all kinds, classes, varieties, nature of Drugs including pharmaceuticals preparation and formulations, and such other products or things relating to or connected with the above activities. To undertake turnkey operations, market survey, pilot scale studies, overseas assignment relating to or connected therewith.
Clients Profiles :
Concord Drugs Ltd acquired an impressive line of customers. Some of them are:
|Name of the Client||Description of business activity|
|Veritaz Healthcare Ltd, Hyderabad.||Veritaz Healthcare Limited is currently outsourcing productionThe company believes and puts to practice sound marketing strategies tested over time. The belief is that a customer not just buys a product, but buys an experience that makes him satisfied and happy. The company believes that Doctors are discerning customers and ethics is an area that it does not compromise. The brand building route will be given emphasis as a result of which quite a few brands should be made to climb the topper charts both in CMARC and ORG rankings.||Crescent Therapeutics Ltd, Hyderabad.||Crescent Therapeutics Limited is the manufacturing arm of the Crescent Group, a young, vibrant organization that is committed to deliver quality healthcare and customer service beyond compare.
Crescent Therapeutics has a world-class oral solid dosage form manufacturing facility for tablets, capsules, DC granules, pellets and nutraceuticals approvable by regulatory authorities of developed countries. With a client base of over thirty leading domestic pharmaceutical companies, the company is aggressively pursuing the rapidly growing contract manufacturing and formulation development space.
|Cian Healthcare Pvt. Ltd, Pune.||Cian Healthcare Pvt. Ltd is one of the Top Manufacturing Pharmaceutical Companies from Pune (Maharashtra); India with a competitive range of innovative healthcare products comprising of a wide range of Tablets, Capsules, Syrups, Dry Powder Injectables, Lotions, Creams, Energy Drinks, Medicated Soaps, Medicated Shampoos, Veterinary Products. They have 150+ Promotional Distributors all over India for our own brands & 20+ Third Party Manufacturers. We are also entering in to the Export Market.|
|Medichem Pharma, Vijayawada||Medichem Pharma is Vijayawada based Formulations marketing Company having wide range of products like Tablets, Capsules & Dry Syrups.|
|Sunlife Sciences Pvt. Ltd, Bangalore.||Sunlife Sciences Pvt. Ltd is a Bangalore based Company having wide range of products throughout the India. Also they are having their own manufacturing unit at Roorkee, Uttarakhand. They are doing marketing wide range of products i.e. Tablets, Capsules, Syrups, Liquid Injections, Dry Powder Injections, Lotions, Creams, etc.|
|Srinivasa Medical Agencies, Hyderabad||Srinivasa Medical Agencies is a Hyderabad based leading Pharma Marketing Company. They are marketing Products their own brands along with other Generic products throughout India.|
Company’s philosophy on code of Corporate Governance:
Concord Drugs Limited believes in conducting its affairs with the highest level of integrity, with proper authorizations, professionalism, accountability and transparency. The business operations of FGIS are conducted not to benefit any particular interest group but for the benefit of all stakeholders. All matters of strategy, annual budgets, significant developments etc., are routinely placed before the Board. The Audit and Share Transfer and Grievance Committees regularly meet to consider aspects relevant to each committee whereas the Remuneration Committee meets based on need.
|Corporate Governance (31-12-2011)||Corporate Governance (31-03-2012)||Corporate Governance (31-03-2013)||Corporate Governance (31-03-2014)||Corporate Governance (31-03-2015)|
|Corporate Governance (30-06-2012)||Corporate Governance (30-06-2013)||Corporate Governance (30-06-2014)|
|Corporate Governance (30-09-2012)||Corporate Governance (30-09-2013)||Corporate Governance (30-09-2014)|
|Corporate Governance (31-12-2012)||Corporate Governance (31-12-2013)||Corporate Governance (31-12-2014)|
|Sl.No||Name of Directors||Category||Designation|
|1.||S. Nagi Reddy||Executive, Non Independent||Managing Director|
|2.||K. Ramachandra Reddy||Executive, Non Independent||Wholetime Director|
|3.||S. Koni Reddy||Non-Executive, Non Independent||Director & IFO|
|4.||M. Eswar Rao||Non-Executive, Independent||Director|
|5.||P. Venkatram Reddy||Non-Executive, Independent||Director|
|6.||Panthamvar Chandra Kala||Non-Executive, Independent||Director|
This Model Code of Conduct for Directors & Senior Management personnel is a guide to help Directors on the Board & Senior Management team of the Company to live up to Company’s ethical standards. The rules and principles set forth in this Code are general in nature and the compliance with the Code shall be ensured read with other applicable policies and procedures of the Company. This model code of conduct may be reviewed by the Board from time to time to keep in pace with the regulatory environment and any amendments to this Code, shall be approved by the Board of Directors.
This Code of Conduct (the “Code”) for the Board of Directors and Senior Management shall be applicable to each member of the Board of Directors of Concord Drugs Limited (the “Company”) and functional heads of the Company, or such other employees of the Company as may be designated as members of the “senior management” for the purposes of the Code by the Managing Director of the Company from time to time (hereinafter referred to as Senior Management”).References herein to the term “Company” shall include its subsidiaries, joint ventures and associates unless the context otherwise requires.
The Code has been drafted in accordance with the provisions of Clause 49 of the Listing Agreement to be entered into by the Company with the Stock Exchange/s to:
The Board of Directors of the Company is entrusted with the fiduciary responsibility of oversight of the affairs of the Company. As Directors of the Company, they have a duty to make decisions and implement policies in the best interests of the Company and its stakeholders.
Therefore, the Directors and Senior Management are obliged to carry out their duties in an honest, fair, diligent and ethical manner, within the scope of the authority conferred upon them and in accordance with the laws, rules, regulations, agreements, guidelines, standards and internal policies and procedures.
The Directors & Senior Management personnel are required to act with utmost care, skill and diligence and in accordance with the highest standards of personal and professional integrity and legal conduct, when acting on behalf of the Company or in connection with the Company’s business or operations and at social events.
Conflict of Interest:
The Directors and senior management personnel are expected to avoid and disclose any activity or association that creates or appears to create a conflict between the personal interests and the Company’s business interests. A Conflict of interest exists where the interests or benefits of one person or entity conflict with the interests or benefits of the Company.
Relationships with prospective or existing suppliers, contractors, customers, competitors or regulators must not affect the independent and sound judgment on behalf of the Company. Directors & the Senior Management personnel are required to disclose to the Board any situation that may be, or appear to be, a conflict of interest. When in doubt, Disclosure is the best way out.
It is the general obligation of the Directors to conduct the business and operations of the Company in accordance with the laws, rules, regulations, agreements, guidelines; standards including Accounting Standards governing its operations in the geographies where the Company operates. The Directors and Senior Management personnel shall acquire appropriate knowledge of the legal requirements relating to their duties sufficient to enable them to perform their obligations diligently.
The Directors and Senior Management personnel shall also comply with the internal policies and procedures of the Company to the extent applicable to them including but not limited to compliance with Prohibition of Insider Trading policy of the Company.
Confidential Information and Corporate Disclosure Policy:
The Directors and Senior Management personnel must maintain the confidentiality of information relating to the affairs of the Company until and unless authorized or legally required to disclose such information; and shall not use confidential information for their personal advantage.
The Directors and Senior Management are obliged to ensure continuous, timely and adequate disclosure of necessary information to the Company at regular intervals in respect of declarations required to be made under Applicable Laws, including the Companies Act, 1956 as amended, details of related parties and details of any material financial and commercial transactions where a conflict of interest is likely.
Fair Dealing, Use and Protection of Company’s Assets:
The Directors and Senior Management personnel are obligated to deal fairly and honestly with each other, the Company’s associates and with the Company’s customers, suppliers, competitors and other third parties. Directors and Senior Management personnel shall not take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation or any other unfair dealing or practice.
The Directors and Senior Management are required to protect the Company’s assets and properties, records and systems, including intellectual property and ensure their efficient use. The assets of the Company shall be used for legitimate business purposes and shall not be used for personal purposes. Incidental personal use, if reasonable, does not amount to violation of the code.
Compliance and Violation of Code of Conduct:
It is the duty and obligation of every Director and Senior Management person to comply with this code of conduct and he/she shall acknowledge and affirm ongoing compliance with the code on an annual basis. This code of conduct shall be posted on the website of the Company.
Any violations of this code shall be promptly reported to the Chairman of the Board or any other person appointed for this purpose. The Company will take appropriate action against any Director member or the Senior Management whose actions are found to violate the Code, after giving him/her a reasonable opportunity of being heard.
Waivers and Amendments of the Code:
We are committed to continuously review and update our policies and procedures. Therefore, this Code is subject to modifications. Any amendment / inclusion or wavier of any provision of this Code must be approved by the Company’s Board of Directors and promptly disclosed, if required pursuant to Applicable Laws.
Each of the Directors and members of the Senior Management and every other person to whom this Code is made applicable, shall file with the Company Secretary of the Company, or any other person appointed for this purpose, a certificate addressed to the Chairman, by the 1st of April of every year, confirming his/her compliance with the provisions of this Code.
The Directors and Senior Management personnel shall read and fully understand this model code of conduct and comply with the policies procedures and principles contained therein.
In line with the commencement of the Companies Act, 2013 in August, 2013 and SEBI (Prohibition of Insider Trading) Regulations, 2015 issued on 15th January, 2015, the followingCode of Conduct (hereinafter referred to as the “Code”) has been adopted by the Board of Directors of the Company through circular resolution held on May 12,2015 and shall be effective from 15th May, 2015.
Click Here to read more